Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATMICRO: Psilocybin Microdosing Study
NCT05160220Completed
- Sponsor
- CONICET
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of psilocybin (2 arms), sponsored by CONICET. Primary endpoints: Resting state oscillations measured with EEG at 1 week, Attention at 1 week and 7 more. Started Jan 2021; status: completed.
02
Drugs
psilocybin
Beyond the preview
Go deeper on NCT05160220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160220.